We solved the crystal structure of Burkholderia pseudomallei acute phase antigen BPSL2765 in the context of a structural vaccinology study, in the area of melioidosis vaccine development. Based on the structure, we applied a recently developed method for epitope design that combines computational epitope predictions with in vitro mapping experiments and successfully identified a consensus sequence within the antigen that, when engineered as a synthetic peptide, was selectively immunorecognized to the same extent as the recombinant protein in sera from melioidosis-affected subjects. Antibodies raised against the consensus peptide were successfully tested in opsonization bacterial killing experiments and antibody-dependent agglutination tests of B. pseudomallei. Our strategy represents a step in the development of immunodiagnostics, in the production of specific antibodies and in the optimization of antigens for vaccine development, starting from structural and physicochemical principles.
Exploiting the Burkholderia pseudomallei acute phase antigen BPSL2765 for structure-based epitope discovery/design in structural vaccinology / L.J. Gourlay, C. Peri, M. Ferrer Navarro, O. Conchillo Solé, A. Gori, D. Rinchai, R.J. Thomas, O.L. Champion, S.L. Michell, C. Kewcharoenwong, A. Nithichanon, P. Lassaux, L. Perletti, R. Longhi, G. Lertmemongkolchai, R.W. Titball, X. Daura, G. Colombo, M. Bolognesi, C. Peri. - In: CHEMISTRY & BIOLOGY. - ISSN 1074-5521. - 20:9(2013 Sep 19), pp. 1147-1156. [10.1016/j.chembiol.2013.07.010]
Exploiting the Burkholderia pseudomallei acute phase antigen BPSL2765 for structure-based epitope discovery/design in structural vaccinology
L.J. Gourlay;C. Peri;A. Gori;P. Lassaux;L. Perletti;G. Colombo;M. Bolognesi;C. Peri
2013
Abstract
We solved the crystal structure of Burkholderia pseudomallei acute phase antigen BPSL2765 in the context of a structural vaccinology study, in the area of melioidosis vaccine development. Based on the structure, we applied a recently developed method for epitope design that combines computational epitope predictions with in vitro mapping experiments and successfully identified a consensus sequence within the antigen that, when engineered as a synthetic peptide, was selectively immunorecognized to the same extent as the recombinant protein in sera from melioidosis-affected subjects. Antibodies raised against the consensus peptide were successfully tested in opsonization bacterial killing experiments and antibody-dependent agglutination tests of B. pseudomallei. Our strategy represents a step in the development of immunodiagnostics, in the production of specific antibodies and in the optimization of antigens for vaccine development, starting from structural and physicochemical principles.File | Dimensione | Formato | |
---|---|---|---|
Gourlayetal_2013.pdf
accesso riservato
Descrizione: Articolo principale
Tipologia:
Publisher's version/PDF
Dimensione
1.61 MB
Formato
Adobe PDF
|
1.61 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.